IPHA 財務： Innate Pharma SA AI 分析

Q: Innate Pharma SA 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），Innate Pharma SA 的總資產為 $111，淨損失為 $-49

Q: IPHA 的關鍵財務比率是什麼？

Innate Pharma SA 的流動比率為 1.08，淨利潤率為 -408.33，每股銷售為 $0.14。

Q: Innate Pharma SA 的收入按細分市場或地理位置如何劃分？

Innate Pharma SA 最大收入來源為 Research and Development of Pharmaceutical Products，在最近的收益報告中收入為 20,121,000。就地區而言，France 是 Innate Pharma SA 的主要市場，收入為 20,121,000。

Q: Innate Pharma SA 是否盈利？

無，根據最新的財務報表，Innate Pharma SA 的淨損失為 $-49

Q: Innate Pharma SA 有負債嗎？

是的，Innate Pharma SA 的負債為 102

Q: Innate Pharma SA 的流通股有多少？

Innate Pharma SA 的總流通股為 83.81

首頁

股票

IPHA

IPHA 財務

Innate Pharma SA

$1.74

-0.96%

$-0.01

收盤價：Jan 16, 16:00:00 GMT-5

$1.75

0.4%

$0

盤後：Jan 16, 20:00:00 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

$1.76

開盤價

$1.8

當日範圍

$1.7 - $1.8

52週區間

$1.62 - $2.63

交易量

19.8K

平均成交量

200.4K

每股盈餘 (TTM)

-0.64

股息收益率

市值

$161.3M

什麼是 IPHA？

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

功能特性

交易策略

資源

市場

收入

資產負債表

現金流量

年度

每季

IPHA 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	6	12	51	49	12	56
營收年增率 (YoY)	-75%	-76%	4%	308%	-79%	-18%
營收成本	3	3	2	3	3	3
毛利	2	9	49	45	9	52
銷售、一般及管理費用	18	18	16	20	23	17
研發	40	48	49	45	41	37
營業費用	53	61	61	62	56	51
其他非營業收入 (費用)	0	1	1	-1	1	0
稅前淨利	-46	-49	-7	-57	-45	0
所得稅費用	0	0	0	0	0	0
淨利	-46	-49	-7	-58	-52	-63
淨利成長	35%	600%	-88%	12%	-17%	215%
稀釋後流通股數	86.93	81.05	80.45	79.63	79.54	78.93
股數年變動 (YoY)	8%	1%	1%	0%	1%	18%
每股盈餘 (稀釋)	-0.54	-0.61	-0.09	-0.72	-0.66	-0.81
每股盈餘成長率	30%	549%	-87%	10%	-19%	161%
自由現金流	-41	-7	-34	-20	-59	-63
每股自由現金流	--	--	--	--	--	--
毛利率	33.33%	75%	96.07%	91.83%	75%	92.85%
營業利益率	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
淨利率	-766.66%	-408.33%	-13.72%	-118.36%	-433.33%	-112.5%
自由現金流利潤率	-683.33%	-58.33%	-66.66%	-40.81%	-491.66%	-112.5%
EBITDA	-49	-50	-7	29	-43	57
EBITDA 利潤率	-816.66%	-416.66%	-13.72%	59.18%	-358.33%	101.78%
EBITDA 中的折舊與攤銷	1	1	5	45	4	56
EBIT	-50	-51	-12	-16	-47	1
EBIT 利潤率	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
有效稅率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Innate Pharma SA 的關鍵財務報表是什麼？



IPHA 的關鍵財務比率是什麼？



Innate Pharma SA 的收入按細分市場或地理位置如何劃分？



Innate Pharma SA 是否盈利？



Innate Pharma SA 有負債嗎？



Innate Pharma SA 的流通股有多少？



Innate Pharma SA（IPHA）價格

IPHA 股價走勢圖